Fenofibrate + Statin Found to Reduce Diabetic Retinopathy Progression
Diabetic retinopathy is a significant cause of vision impairment and is predicted to become an increasingly large global public health problem. Diabetic retinopathy often affects those of working age and can have significant health, social and economic implications. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-a) agonist, has been suggested as an adjunctive therapeutic option for diabetic retinopathy in patients with diabetes and existent diabetic retinopathy.
Modern Medicine – Issue 6 2023
